Clinical Trials Logo

Clinical Trial Summary

A multicenter, open labeled randomized, phase II trial comparing FOLFOXIRI and mFOLFOX6 as adjuvant treatment for high risk stage III (pT4N1/2 or pTanyN2) colon cancer

Clinical Trial Description

After inclusion and exclusion criteria have been fulfilled and the patient consent has been obtained, the patient will be included and randomized to mFOLFIRINOX or mFOLFOX 6 with a 1:1 ratio. Arm A: FOLFOXIRI Arm B: mFOLFOX ;

Study Design

Related Conditions & MeSH terms

NCT number NCT05179889
Study type Interventional
Source Chungnam National University Hospital
Contact Kyung Ha Lee
Phone 821042141415
Email [email protected]
Status Recruiting
Phase Phase 2/Phase 3
Start date July 6, 2021
Completion date March 15, 2028

See also
  Status Clinical Trial Phase
Completed NCT00309530 - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C Phase 3
Completed NCT04342676 - Lymph Node Ratio and Kras Mutation in R Colon Cancer Phase 3
Recruiting NCT05194878 - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers Phase 3
Not yet recruiting NCT04488159 - Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Phase 3